NASDAQ:MRUSMerus Stock Price, Forecast & News

Merus' stock was trading at $14.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MRUS shares have increased by 8.8% and is now trading at $15.82. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Merus.

Merus is scheduled to release its next quarterly earnings announcement on Monday, August 17th 2020. View our earnings forecast for Merus.

Merus NV (NASDAQ:MRUS) released its quarterly earnings data on Monday, May, 11th. The biotechnology company reported ($0.68) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.54) by $0.14. The biotechnology company earned $6.30 million during the quarter, compared to the consensus estimate of $8.05 million. Merus had a negative return on equity of 62.96% and a negative net margin of 225.21%. View Merus' earnings history.

3 Wall Street analysts have issued 1-year price objectives for Merus' stock. Their forecasts range from $16.00 to $23.00. On average, they expect Merus' stock price to reach $20.67 in the next twelve months. This suggests a possible upside of 30.6% from the stock's current price. View analysts' price targets for Merus.

News headlines about MRUS stock have been trending somewhat negative this week, InfoTrie reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Merus earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Merus.

Merus saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 252,600 shares, an increase of 11.7% from the May 31st total of 226,100 shares. Based on an average daily trading volume, of 157,900 shares, the days-to-cover ratio is presently 1.6 days. Approximately 1.3% of the shares of the stock are sold short. View Merus' Current Options Chain.

Some companies that are related to Merus include Prestige Consumer Healthcare (PBH), Eidos Therapeutics (EIDX), Xencor (XNCR), Aurinia Pharmaceuticals (AUPH), Myovant Sciences (MYOV), Ligand Pharmaceuticals (LGND), Madrigal Pharmaceuticals (MDGL), Passage Bio (ZNTL), Y-mAbs Therapeutics (YMAB), I-Mab (IMAB), Akebia Therapeutics (AKBA), Intra-Cellular Therapies (ITCI), Ironwood Pharmaceuticals (IRWD), Zymeworks (ZYME) and Epizyme (EPZM). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Exelixis (EXEL), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP) and Fate Therapeutics (FATE).

(MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRUS stock can currently be purchased for approximately $15.82.

Merus has a market capitalization of $459.44 million and generates $31.13 million in revenue each year. The biotechnology company earns $-55,150,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Merus employs 98 workers across the globe.

The official website for Merus is www.merus.nl.

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]